

January 28, 2016
Shionogi & Co., Ltd.
Nissan Chemical Industries, Ltd.

Shionogi and Nissan Chemical enter into strategic research collaboration for novel antifungal drug candidates

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereinafter called “Shionogi”) and Nissan Chemical Industries, Ltd. (Head Office: Tokyo, Japan; President & CEO: Kojiro Kinoshita; hereinafter called “Nissan Chemical”), today announced the conclusion of the strategic research collaboration agreement for novel antifungal drug candidates.

In antifungal therapeutic area, there still remain unmet medical needs and more effective and safer drugs are required. For example, the investigations of the Japan Nosocomial Infections Surveillance by Ministry of Health, Labour and Welfare on 2013 and 2014 have reported that *Candida Albicans* was detected from blood samples of hospital patients with approximately the same frequency in *Pseudomonas aeruginosa* and *Enterococcus*. Also, the National Institute of Infectious Diseases has reported on 2013 that *Aspergillus* was separated from compromised patients at a high frequency and that the lethality of *Aspergillus* was as high as *Candida*.

Shionogi has strengths in small molecule drug discovery and focuses on infectious disease area. Nissan Chemical has high capability of conducting SAR (Structure-Activity Relationship) study based on high potentiality of designing and synthesizing small molecule compounds. Both two companies will strive to provide best possible antifungal drugs to patients as early as possible, combining both companies’ strengths to generate drug candidates. Shionogi and Nissan Chemical will aim to achieve effective resource allocation and enrichment of research programs by positively utilizing risk-sharing collaborative researches with industry and academia.

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. has been researching, developing and distributing innovative infectious disease drugs for more than fifty years. Shionogi is a major research-driven pharmaceutical company dedicated to placing the highest value on patients based on its corporate philosophy of “supply the best possible medicine to protect the health and wellbeing of the patients we serve,” Shionogi’s research and development currently targets two therapeutic areas: infectious diseases, and pain/CNS disorders. In addition, Shionogi is engaged in new research areas such as obesity/geriatric metabolic disease and oncology/immunology. Contributing to the health and QOL of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit <http://www.shionogi.co.jp>

About Nissan Chemical Industries, Ltd.

Nissan Chemical Industries, Ltd. is now moving forward to develop new products and businesses through utilization of our core technologies as the chemical company with our corporate vision of becoming "a corporate group that contributes to human survival and development". Nissan Chemical entered into the pharmaceutical business in 1982, and launched an external preparation of ketoprofen, a Ca antagonist and a statin agent with a strong LDL cholesterol reduction. We keep trying research and development for innovative medicines by using precise organic synthesis technology, the strategic chemical library and the state-of-the-art evaluation technology for the smile and precious life around the world. For more details, please visit <http://www.nissanchem.co.jp/eng/>

[Contact]

Corporate Communications, Shionogi & Co., Ltd.
Osaka Tel: +81-6-6209-7885 Fax: +81-6-6229-9596
Tokyo Tel: +81-3-3406-8164 Fax: +81-3-3406-8099

Corporate Planning, Nissan Chemical Industries, Ltd.
Tel: +81-3-3296-8320